These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 15854553)
1. [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma]. Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Xu JM; Qian YZ; Qian QJ Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):468-72. PubMed ID: 15854553 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin]. Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284 [TBL] [Abstract][Full Text] [Related]
3. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma. Li GC; Yang JM; Nie MM; Su CG; Sun LC; Qian YZ; Fang GE; Sham J; Wu MC; Qian QJ Chin Med J (Engl); 2005 Feb; 118(3):179-85. PubMed ID: 15740644 [TBL] [Abstract][Full Text] [Related]
4. Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Liao GQ; Qu YM; Xie GQ; Li MY; Ge FJ; Qian QJ World J Gastroenterol; 2008 Feb; 14(8):1274-9. PubMed ID: 18300357 [TBL] [Abstract][Full Text] [Related]
5. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667 [TBL] [Abstract][Full Text] [Related]
6. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637 [TBL] [Abstract][Full Text] [Related]
7. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958 [TBL] [Abstract][Full Text] [Related]
9. [In vitro gene therapy of hepatocellular carcinoma using replication-defective and tumor-specific replication-competent adenovirus carrying interleukin-12 gene]. Wang XH; Yang JM; Cui ZF; Wang WG; Wu MC; Qian QJ Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):581-4. PubMed ID: 15634515 [TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456 [TBL] [Abstract][Full Text] [Related]
11. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559 [TBL] [Abstract][Full Text] [Related]
12. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma]. Song Y; Shen K; He CX Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242 [TBL] [Abstract][Full Text] [Related]
14. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895 [TBL] [Abstract][Full Text] [Related]
15. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism]. Tang YX; Chen Y; Gu JF; Qi R; Zou WG; Jiang LL; Liu XY Ai Zheng; 2005 May; 24(5):536-42. PubMed ID: 15890093 [TBL] [Abstract][Full Text] [Related]
16. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma]. Song Y; Shen K; Yu JR Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307 [TBL] [Abstract][Full Text] [Related]
17. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Zhang Q; Nie M; Sham J; Su C; Xue H; Chua D; Wang W; Cui Z; Liu Y; Liu C; Jiang M; Fang G; Liu X; Wu M; Qian Q Cancer Res; 2004 Aug; 64(15):5390-7. PubMed ID: 15289347 [TBL] [Abstract][Full Text] [Related]
18. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously. Qian Q; Sham J; Che X; Xu J; Xue H; Cui Z; Zhu B; Wu M Chin Med J (Engl); 2002 Aug; 115(8):1213-7. PubMed ID: 12215295 [TBL] [Abstract][Full Text] [Related]
19. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. Zheng X; Rao XM; Snodgrass CL; McMasters KM; Zhou HS Cancer Gene Ther; 2006 Jun; 13(6):572-83. PubMed ID: 16341141 [TBL] [Abstract][Full Text] [Related]
20. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Bilsland AE; Merron A; Vassaux G; Keith WN Cancer Res; 2007 Feb; 67(3):1299-307. PubMed ID: 17283167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]